Abstract
The androgen receptor (AR) plays a pivotal role in the progression of prostate cancer from the androgen-dependent to the castration-resistant state, making it a potential target for therapy. In this chapter, we describe the preparation and use of sublines of LNCaP and C4-2 human prostate cancer cells which have been engineered to stably express a doxycycline (DOX)-inducible AR shRNA in order to study the in vitro and in vivo effects of AR knockdown.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Base Sequence
-
Biological Assay
-
Cell Line, Tumor
-
Cell Proliferation
-
Cloning, Molecular
-
Doxycycline / pharmacology
-
Gene Expression Regulation / drug effects
-
Gene Knockdown Techniques
-
Gene Silencing*
-
Gene Transfer Techniques
-
Genetic Vectors / genetics
-
HEK293 Cells
-
Humans
-
Male
-
Mice
-
Mice, Nude
-
RNA, Small Interfering / genetics
-
RNA, Small Interfering / metabolism
-
Receptors, Androgen / genetics*
-
Receptors, Androgen / metabolism*
-
Recombination, Genetic
-
Repressor Proteins / drug effects
-
Repressor Proteins / genetics
-
Transcription, Genetic
-
Xenograft Model Antitumor Assays
Substances
-
RNA, Small Interfering
-
Receptors, Androgen
-
Repressor Proteins
-
tetracycline resistance-encoding transposon repressor protein
-
Doxycycline